676491-46-6

Basic information

• Product Name: 1H-Pyrrolo[2,3-c]pyridine, 4-Methoxy-7-(3-Methyl-1H-1,2,4-triazol-1-yl)-
• Synonyms: 1H-Pyrrolo[2,3-c]pyridine, 4-Methoxy-7-(3-Methyl-1H-1,2,4-triazol-1-yl)-;4-Methoxy-7-(3-Methyl-1,2,4-triazol-1-yl)-6-azaindole;1H-Pyrrolo[2,3-c]pyridine, 4-Methoxy-7-(3-Methyl-1H-1,2,4-triazol-1-yl)-10;1-{4-methoxy-1H-pyrrolo[2,3-c]pyridin-7-yl}-3-methyl-1H-1,2,4-triazole;4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridine
• CAS NO: 676491-46-6
• Molecular Formula: C₁₁H₁₁N₅O
• Molecular Weight: 229.23794
• Mol File: 676491-46-6.mol

Chemical Properties

• Boiling Point: 525.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 13.04±0.40(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[2,3-c]pyridine, 4-Methoxy-7-(3-Methyl-1H-1,2,4-triazol-1-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-c]pyridine, 4-Methoxy-7-(3-Methyl-1H-1,2,4-triazol-1-yl)-(676491-46-6)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-c]pyridine, 4-Methoxy-7-(3-Methyl-1H-1,2,4-triazol-1-yl)-(676491-46-6)

Safety Data

• Hazardous Substances Data: 676491-46-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[2,3-c]pyridine, 4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)is utilized as a lead compound in drug discovery for its capacity to modulate biological pathways. The specific mechanisms of action and therapeutic applications of 1H-Pyrrolo[2,3-c]pyridine, 4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)- are under active research and investigation, with the aim of identifying its potential in treating various diseases and conditions.
Given the compound's heterocyclic nature and the presence of diverse functional groups, it may also be employed in the development of targeted therapies, where its structure can be optimized to interact with specific biological targets, such as enzymes or receptors, to elicit desired pharmacological effects.

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 

Downstream Products

• 1392514-36-1 C₂₁H₁₈ClN₅O₄S 
• 701213-36-7 1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-ethane-1,2-dione 
• 1426310-90-8 1-(5-benzoylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione 
• 1392514-37-2 C₃₁H₂₈ClN₇O₄S 
• 1392514-39-4 C₂₅H₂₄ClN₇O₄ 

Relevant articles and documents

Kinetic characterization of novel HIV-1 entry inhibitors: Discovery of a relationship between off-rate and potency

The entry of HIV-1 into permissible cells remains an extremely attractive and underexploited therapeutic intervention point. We have previously demonstrated the ability to extend the chemotypes available for optimization in the entry inhibitor class using computational means. Here, we continue this effort, designing and testing three novel compounds with the ability to inhibit HIV-1 entry. We demonstrate that alteration of the core moiety of these entry inhibitors directly influences the potency of the compounds, despite common proximal and distal groups. Moreover, by establishing for the first time a surface plasmon resonance (SPR)-based interaction assay with soluble recombinant SOSIP Env trimers, we demonstrate that the off-rate (kd) parameter shows the strongest correlation with potency in an antiviral assay. Finally, we establish an underappreciated relationship between the potency of a ligand and its degree of electrostatic complementarity (EC) with its target, the Env complex. These findings not only broaden the chemical space in this inhibitor class, but also establish a rapid and simple assay to evaluate future HIV-1 entry inhibitors.

Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies

The development of two enabling routes that led to the production of >1000 kg of BMS-663068 (3) is described. The route identified for the initial 100 kg delivery to support development activities and initial clinical trials involved the conversion of 2-amino-4-picoline to the parent active pharmaceutical ingredient (API), followed by pro-drug installation and deprotection. To eliminate the problematic isolation of the parent API and synthesis of di-t-butyl(chloromethyl)phosphate, a second-generation pro-drug installation route was developed which involved the conversion of a late-stage common intermediate to an N(1)-thioether derivative followed by chloromethylation, displacement with di-t-butylpotassium phosphate, and deprotection. This second strategy resulted in the multikilogram scale preparation of the API in 14 linear steps and ～7% overall yield.

Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement

Demand remains for new inhibitors of HIV-1 replication and the inhibition of HIV-1 entry is an extremely attractive therapeutic approach. Using field-based bioisosteric replacements, we have further extended the chemotypes available for development in the HIV-1 entry inhibitor class. Moreover, using field-based disparity analysis of the compounds, 3D structure-activity relationships were derived that will be useful in the further development of these inhibitors towards clinical utility.

Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement

With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. Using the combination of a field-derived bioactive conformation template to perform virtual screening and iterative bioisosteric replacements, coupled with in silico predictions of absorption, distribution, metabolism, and excretion, we have identified new leads for HIV-1 entry inhibitors.